Drugs / DC/MM Fusion Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07377435 | Jan 2026 → Mar 2028 expected | plasma cell myeloma, refractory plasma cell neoplasm | David Avigan | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC/MM Fusion Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07377435 ↗ |
| Modality | Vaccine | “a type of personalized cancer vaccine” NCT07377435 ↗ |
| Route | Subcutaneous | “via subcutaneous injection (under the skin)” NCT07377435 ↗ |